Current FDA-approved gene therapy approaches, such as the RPE65-targeted therapy approved for Leber congenital amaurosis, may have limited applicability to this Turkish cohort based on the genetic spectrum observed [36,37]. The gene discussed is RPE65; the disease is Leber congenital amaurosis.